{"id":"thyrotropin-alfa","rwe":[],"_fda":{"id":"7d9af689-848b-3aea-e053-2a91aa0a70d2","set_id":"03dc86d3-575f-4c65-b06d-2613efbcd943","openfda":{"nui":["M0000499","N0000175941","N0000175945","M0021504","N0000009705","N0000175828","M0015703","N0000175949","M0021496"],"upc":["0317089349181"],"unii":["O80TY208ZW","6P669D8HQ8","L7A49804ZQ","A1ED6W905I","K0U68Q2TXA","2P299V784P","Q51BO43MG4","QH51543Y7U","817L1N4CKP","JL5DK93RCL","02R4V6T25Y","P658DCA9XD","1JQS135EYN","47E5O17Y3R","6EC706HI7F","8558G7RUTR","3T006GV98U","KU1MBT4JJB","398IYQ16YV","GV54Q19G55","N6R0856Z79","AVX3D5A4LM"],"route":["ORAL"],"spl_id":["7d9af689-848b-3aea-e053-2a91aa0a70d2"],"brand_name":["GUNA-GERIATRICS"],"spl_set_id":["03dc86d3-575f-4c65-b06d-2613efbcd943"],"package_ndc":["17089-349-18"],"product_ndc":["17089-349"],"generic_name":["1,4-BENZOQUINONE - ARNICA MONTANA - OXYTOCIN - BARIUM CARBONATE - BARIUM OXALOSUCCINATE - CORTICOTROPIN - LEAD - LEVOTHYROXINE - LUTRELIN - MALIC ACID - MELATONIN - NEUROTROPHIN-3 - NEUROTROPHIN-4 - PHENYLALANINE - PORK LIVER - PYRUVIC ACID - RINFABATE - SUS SCROFA ADRENAL GLAND - SUS SCROFA FRONTAL LOBE - SUS SCROFA HYPOTHALAMUS - THYROTROPIN ALFA - BRAIN-DERIVED NEUROTROPHIC FACTOR HUMAN -"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Adrenocorticotropic Hormone [CS]","Thyroxine [CS]","Oxytocin [CS]","Thyrotropin [CS]"],"pharm_class_pe":["Increased Uterine Smooth Muscle Contraction or Tone [PE]"],"substance_name":["ARNICA MONTANA","BARIUM CARBONATE","BARIUM OXALOSUCCINATE","BRAIN-DERIVED NEUROTROPHIC FACTOR HUMAN","CORTICOTROPIN","LEAD","LEVOTHYROXINE","LUTRELIN","MALIC ACID","MELATONIN","NEUROTROPHIN-3","NEUROTROPHIN-4","OXYTOCIN","PHENYLALANINE","PORK LIVER","PYRUVIC ACID","QUINONE","RINFABATE","SUS SCROFA ADRENAL GLAND","SUS SCROFA FRONTAL LOBE","SUS SCROFA HYPOTHALAMUS","THYROTROPIN ALFA"],"pharm_class_epc":["Adrenocorticotropic Hormone [EPC]","l-Thyroxine [EPC]","Oxytocic [EPC]","Thyroid Stimulating Hormone [EPC]"],"manufacturer_name":["Guna spa"],"is_original_packager":[true]},"purpose":["For the temporary relief symptoms due to aging, scuh as: poor memory impaired concentration"],"version":"2","warnings":["WARNINGS Stop use and ask doctor if symptoms persist more than 5 days. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Contains ethyl alcohol 30%"],"questions":["QUESTIONS Questions?: info@gunainc.com, tel. (484) 223-3500"],"effective_time":"20181222","active_ingredient":["ACTIVE INGREDIENTS/PURPOSE ACTH 6X ADRENAL SUPPORT ARNICA MONTANA 6X ANTI-INFLAMMATORY BARIUM OXALOSUCCINATE 3X FORGETFULNESS BARYTA CARBONICA 6X IMPROVES MENTAL ATTENTION BRAIN DERIVED NEUROTROPHIC FACTOR 4C HELPS MENTAL ACTIVITY DL-MALIC ACID 3X PROMOTE CELL METABOLISM FRONTAL LOBE 6X STIMULATES MENTAL ALERTNESS GLANDULA SUPRARENALIS 6X DETOXIFICATION HEPAR 6X DETOXIFICATION HYPOTHALAMUS 6X IMPROVES MENTAL ATTENTION INSULINE-LIKE GROWTH FACTOR-1 4C ENHANCES PROTEIN ANABOLISM LUTEINIZING HORMONE-RELEASING HORMONE 6X HELPS MANAGE STRESS MELATONIN 4C HELPS MANAGE STRESS NEUROTROPHIN 3 4C HELPS MENTAL ACTIVITY NEUROTROPHIN 4 4C HELPS MENTAL ACTIVITY OXYTOCIN 6X STIMULATES SOCIAL RECOGNITION PARABENZOCHINON 3X ANTIOXIDANT PHENYLALANINE 3X STIMULATES MENTAL ALERTNESS PLUMBUM METALLICUM 6X ANTIAGING PYRUVIC ACID 3X ANTIOXIDANT THYROTROPIN-RELEASING HORMONE 6X HELPS MANAGE STRESS THYROXINE T4 6X STIMULATES MENTAL ALERTNESS"],"inactive_ingredient":["Inactive ingredient: Ethyl alcohol 30%."],"indications_and_usage":["USES TAKE 15 MINUTES BEFORE MEALS"],"dosage_and_administration":["DIRECTIONS Take 15 minutes before meals Adults : 20 drops in a little water, 2 times per day"],"spl_product_data_elements":["GUNA-GERIATRICS 1,4-benzoquinone - arnica montana - oxytocin - barium carbonate - barium oxalosuccinate - corticotropin - lead - levothyroxine - lutrelin - malic acid - melatonin - neurotrophin-3 - neurotrophin-4 - phenylalanine - pork liver - pyruvic acid - rinfabate - sus scrofa adrenal gland - sus scrofa frontal lobe - sus scrofa hypothalamus - thyrotropin alfa - brain-derived neurotrophic factor human - QUINONE QUINONE BARIUM OXALOSUCCINATE BARIUM CATION ALCOHOL CORTICOTROPIN CORTICOTROPIN ARNICA MONTANA ARNICA MONTANA BARIUM CARBONATE BARIUM CATION BRAIN-DERIVED NEUROTROPHIC FACTOR HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR HUMAN MALIC ACID MALIC ACID SUS SCROFA FRONTAL LOBE SUS SCROFA FRONTAL LOBE SUS SCROFA ADRENAL GLAND SUS SCROFA ADRENAL GLAND PORK LIVER PORK LIVER SUS SCROFA HYPOTHALAMUS SUS SCROFA HYPOTHALAMUS RINFABATE RINFABATE LUTRELIN LUTRELIN MELATONIN MELATONIN NEUROTROPHIN-3 NEUROTROPHIN-3 NEUROTROPHIN-4 NEUROTROPHIN-4 OXYTOCIN OXYTOCIN PHENYLALANINE PHENYLALANINE LEAD LEAD PYRUVIC ACID PYRUVIC ACID THYROTROPIN ALFA THYROTROPIN ALFA LEVOTHYROXINE LEVOTHYROXINE"],"pregnancy_or_breast_feeding":["PREGNANCY If pregnant or breast-feeding ask a doctor before use"],"keep_out_of_reach_of_children":["WARNINGS Keep this and all medicines out of reach of children"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 5USGER- REV06-24-05-18"]},"tags":[{"label":"Thyroid Stimulating Hormone","category":"class"},{"label":"Biologic","category":"modality"},{"label":"Thyrotropin receptor","category":"target"},{"label":"TSHR","category":"gene"},{"label":"H01AB01","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Serum thyroglobulin level","category":"indication"},{"label":"Sanofi Aventis Us","category":"company"},{"label":"Approved 1950s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"126 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"81 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"67 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"40 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"40 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"36 reports"},{"date":"","signal":"BLOOD THYROID STIMULATING HORMONE DECREASED","source":"FDA FAERS","actionTaken":"28 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Influenza-like symptoms","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Fever","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Chills/Shivering","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Myalgia/Arthralgia","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Malaise","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Rash","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Flushing","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Injection site pain","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Injection site erythema","drugRate":"","severity":"postapproval","organSystem":""},{"effect":"Injection site bruising","drugRate":"","severity":"postapproval","organSystem":""}],"specialPopulations":{"Pregnancy":"Concomitant use of THYROGEN and radioiodine (RAI) is contraindicated in pregnancy. THYROGEN may be used in combination with RAI, but the combination regimen is contraindicated in pregnant women because fetal exposure to RAI can lead to neonatal hypothyroidism, which in some cases is severe and irreversible. Available data from case reports and postmarketing experience with THYROGEN use in pregnant women are insufficient to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.","Geriatric use":"In pooled clinical studies of THYROGEN, 60 patients (12%) were >65 years, and 421 (88%) were <=65 years of age. Results from controlled trials do not indicate difference in the safety and efficacy of THYROGEN between adult patients less than 65 years and those over 65 years of age.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"Elimination of THYROGEN is significantly slower in dialysis-dependent end-stage renal disease patients, resulting in prolonged elevation of TSH levels."},"seriousAdverseEvents":[{"effect":"Nausea (severe)","drugRate":"0.4%","severity":"serious"},{"effect":"Fatigue (severe)","drugRate":"0.4%","severity":"serious"},{"effect":"Asthenia (severe)","drugRate":"0.2%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Sanofi","patents":[{"type":"Biologic Exclusivity","filed":"November 30, 1998","source":"FDA Purple Book","status":"Active","expires":"December 14, 2014","territory":"US","patentNumber":"BLA 020898"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=THYROTROPIN ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:48:57.079968+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:48:57.079871+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:49:20.578667+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:49:02.493034+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:48:57.152125+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:48:56.127657+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=THYROTROPIN ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:49:02.834056+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:48:53.863263+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:48:53.863292+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:14.266095+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:48:53.863298+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:49:04.687427+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thyroid stimulating hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:04.077386+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201533/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:03.738820+00:00"}},"allNames":"thyrogen","offLabel":[],"synonyms":["thyrotropin alfa","thyrogen","thyroid stimulating hormone","thyrotropin"],"timeline":[{"date":"1953-05-26","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"},{"date":"2000-03-09","type":"positive","source":"DrugCentral","milestone":"EMA approval (Sanofi B.V.)"}],"aiSummary":"Thyrotropin alfa (Thyrogen), marketed by Sanofi, is a recombinant human thyrotropin used primarily for meal timing, with a key composition patent expiring in 2028. Its mechanism of action, which involves binding to the thyrotropin receptor on the thyroid gland to stimulate thyroglobulin production, provides a targeted approach for its indication. The primary risk is the lack of revenue data and key trial results, which may limit its market visibility and competitive positioning.","approvals":[{"date":"1953-05-26","orphan":false,"company":"SANOFI AVENTIS US","regulator":"FDA"},{"date":"2000-03-09","orphan":false,"company":"SANOFI B.V.","regulator":"EMA"}],"brandName":"Thyrogen","ecosystem":[{"indication":"Serum thyroglobulin level","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Thyrotropin receptor","targets":[{"gene":"TSHR","source":"DrugCentral","target":"Thyrotropin receptor","protein":"Thyrotropin receptor"}],"modality":"Biologic","drugClass":"Adrenocorticotropic Hormone [EPC]","explanation":"","oneSentence":"","technicalDetail":"Thyrogen (Thyrotropin Alfa) is a recombinant human TSH analogue that binds to the thyrotropin receptor, activating the thyroid-stimulating pathway and increasing serum thyroglobulin levels."},"commercial":{"launchDate":"1953","_launchSource":"DrugCentral (FDA 1953-05-26, SANOFI AVENTIS US)"},"purpleBook":{"bla":"020898","source":"FDA Purple Book","approvalDate":"November 30, 1998","licenseStatus":"Licensed","exclusivityExpiry":"December 14, 2014"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4930","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=THYROTROPIN%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=THYROTROPIN ALFA","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:54:22.525315","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:49:20.578763+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","company":"Genzyme Corporation","brandName":"Thyrogen","isOriginal":false,"marketingStatus":"BLA"}],"competitors":[],"genericName":"thyrotropin alfa","indications":{"approved":[{"id":"thyrotropin-alfa-meal-timing","name":"Meal timing","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":"Thyrogen"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03841617","phase":"PHASE2","title":"The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2019-07-29","conditions":["Thyroid Cancer"],"enrollment":30,"completionDate":"2035-11-01"},{"nctId":"NCT03244956","phase":"PHASE2","title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-12-27","conditions":["Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation"],"enrollment":40,"completionDate":"2026-01-15"},{"nctId":"NCT06440850","phase":"PHASE2","title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-15","conditions":["Thyroid Gland Follicular Carcinoma","Thyroid Gland Oncocytic Carcinoma","Thyroid Gland Papillary Carcinoma"],"enrollment":21,"completionDate":"2026-11-22"},{"nctId":"NCT04495985","phase":"","title":"CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-07-14","conditions":["Thyroid Cancer"],"enrollment":39,"completionDate":"2026-12"},{"nctId":"NCT04873869","phase":"PHASE2","title":"Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)","status":"TERMINATED","sponsor":"Neurocrine Biosciences","startDate":"2022-01-31","conditions":["SCN8A Developmental and Epileptic Encephalopathy Syndrome"],"enrollment":8,"completionDate":"2023-03-17"},{"nctId":"NCT06300203","phase":"PHASE2","title":"Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-03-18","conditions":["Seasonal Allergic Rhinitis"],"enrollment":120,"completionDate":"2026-06-30"},{"nctId":"NCT05128383","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-01-13","conditions":["Keloid"],"enrollment":20,"completionDate":"2025-06-10"},{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":["Infertility, Female","Luteinizing Hormone (LH)"],"enrollment":590,"completionDate":"2026-11-30"},{"nctId":"NCT03215095","phase":"EARLY_PHASE1","title":"RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-07-10","conditions":["Thyroid Cancer"],"enrollment":11,"completionDate":"2026-07"},{"nctId":"NCT05226780","phase":"PHASE2","title":"Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Neurocrine Biosciences","startDate":"2022-07-12","conditions":["SCN8A Developmental and Epileptic Encephalopathy Syndrome"],"enrollment":8,"completionDate":"2026-03"},{"nctId":"NCT02145143","phase":"EARLY_PHASE1","title":"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-05-20","conditions":["Thyroid Carcinoma"],"enrollment":12,"completionDate":"2024-11-21"},{"nctId":"NCT06896617","phase":"PHASE4","title":"Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-02-01","conditions":["Infertilities","Embryo Transfer"],"enrollment":334,"completionDate":"2026-12-20"},{"nctId":"NCT03737253","phase":"NA","title":"Hormone Evaluation in Artificial Reproductive Technology","status":"COMPLETED","sponsor":"Lund University","startDate":"2016-09","conditions":["Female Infertility"],"enrollment":810,"completionDate":"2024-10-02"},{"nctId":"NCT05330130","phase":"PHASE1","title":"Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells","status":"COMPLETED","sponsor":"ART Fertility Clinics LLC","startDate":"2023-07-05","conditions":["Ovarian Function Insufficiency","Fertility Issues","Infertility,Female","Infertility"],"enrollment":6,"completionDate":"2024-06-30"},{"nctId":"NCT04997525","phase":"PHASE4","title":"Estradiol and Progesterone Levels Following Frozen Embryo Transfer","status":"COMPLETED","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2021-04-20","conditions":["Infertility"],"enrollment":305,"completionDate":"2024-12-06"},{"nctId":"NCT05668962","phase":"PHASE2","title":"Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-03-01","conditions":["Thyroid Cancer","Thyroid Carcinoma","Metastatic Thyroid Cancer","Follicular Thyroid Cancer","Unresectable Thyroid Gland Carcinoma","Papillary Thyroid Cancer"],"enrollment":30,"completionDate":"2026-01-01"},{"nctId":"NCT05159908","phase":"PHASE2","title":"A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-11-08","conditions":["Focal Onset Seizure","Focal Onset Epilepsy"],"enrollment":101,"completionDate":"2023-08-21"},{"nctId":"NCT00702520","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04-01","conditions":["Pregnancy","Neonates"],"enrollment":15,"completionDate":"2008-01-15"},{"nctId":"NCT00702338","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-05-15","conditions":["Pregnancy","Neonates"],"enrollment":1,"completionDate":"2008-12-15"},{"nctId":"NCT00696800","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06-27","conditions":["In Vitro Fertilization"],"enrollment":1509,"completionDate":"2008-01-15"},{"nctId":"NCT00702845","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12-28","conditions":["Infertility"],"enrollment":397,"completionDate":"2007-11-15"},{"nctId":"NCT00697255","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-15","conditions":["Ovulation Induction"],"enrollment":8,"completionDate":"2008-05-15"},{"nctId":"NCT06431620","phase":"NA","title":"Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-30","conditions":["Recombinant Human Thyroid Stimulating Hormone"],"enrollment":15,"completionDate":"2026-12-31"},{"nctId":"NCT06405217","phase":"NA","title":"Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-04-20","conditions":["DTC - Differentiated Thyroid Cancer","Thyroid Stimulating; Hormone, C","Radiotherapy; Complications"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT05493293","phase":"PHASE2","title":"Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures","status":"TERMINATED","sponsor":"Neurocrine Biosciences","startDate":"2022-11-09","conditions":["Focal Onset Seizure","Focal Onset Epilepsy"],"enrollment":82,"completionDate":"2024-03-11"},{"nctId":"NCT04971473","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-09-10","conditions":["Differentiated Thyroid Cancer"],"enrollment":201,"completionDate":"2023-07-05"},{"nctId":"NCT04137185","phase":"PHASE1,PHASE2","title":"Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2019-06-10","conditions":["Differentiated Thyroid Cancer"],"enrollment":64,"completionDate":"2020-12-29"},{"nctId":"NCT05670795","phase":"NA","title":"Comparison of Recombinant Follicle Stimulating Hormone and the Combination of Recombinant Follicle Stimulating Hormone With Clomiphene Citrate in Stimulated Intrauterine Insemination Cycles","status":"UNKNOWN","sponsor":"Bezmialem Vakif University","startDate":"2023-01-01","conditions":["Infertility Unexplained"],"enrollment":254,"completionDate":"2024-05-01"},{"nctId":"NCT00415233","phase":"PHASE3","title":"High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"University College, London","startDate":"2006-11","conditions":["Head and Neck Cancer"],"enrollment":438,"completionDate":"2025-07"},{"nctId":"NCT04964284","phase":"PHASE3","title":"Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-10-06","conditions":["Differentiated Thyroid Cancer"],"enrollment":328,"completionDate":"2024-12"},{"nctId":"NCT04447183","phase":"PHASE2","title":"The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.","status":"UNKNOWN","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-11-23","conditions":["Differentiated Thyroid Cancer"],"enrollment":120,"completionDate":"2024-10"},{"nctId":"NCT04858867","phase":"NA","title":"Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-01-10","conditions":["Differentiated Thyroid Cancer"],"enrollment":12,"completionDate":"2025-06-01"},{"nctId":"NCT05638529","phase":"PHASE4","title":"Dual Trigger\" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome","status":"UNKNOWN","sponsor":"Mount Sinai Hospital, Canada","startDate":"2019-05-01","conditions":["Ovarian Hyperstimulation Syndrome","Infertility, Female"],"enrollment":80,"completionDate":"2023-12-31"},{"nctId":"NCT01837745","phase":"PHASE3","title":"Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2013-05-13","conditions":["Low Risk Differentiated Thyroid Cancer"],"enrollment":776,"completionDate":"2030-01-01"},{"nctId":"NCT05316987","phase":"NA","title":"Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-04-30","conditions":["Active Non Segmental Vitiligo"],"enrollment":30,"completionDate":"2022-07-30"},{"nctId":"NCT03660813","phase":"NA","title":"Follicle Size and Oocyte Development","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2018-07-01","conditions":["IVF Treatment"],"enrollment":200,"completionDate":"2021-08-01"},{"nctId":"NCT00454220","phase":"PHASE2","title":"Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-07","conditions":["Multinodular Goiter"],"enrollment":96,"completionDate":"2011-07"},{"nctId":"NCT03252223","phase":"PHASE4","title":"Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-10-02","conditions":["Polycystic Ovary Syndrome","Healthy","Anovulation","Hyperandrogenism"],"enrollment":33,"completionDate":"2021-06-30"},{"nctId":"NCT01319695","phase":"PHASE1,PHASE2","title":"Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2011-01","conditions":["Infertility"],"enrollment":140,"completionDate":"2017-08"},{"nctId":"NCT01846182","phase":"PHASE2","title":"Research Examining Gulf War Illness in Our Nations Service Members","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2015-06-24","conditions":["Gulf War Illness"],"enrollment":112,"completionDate":"2019-08-01"},{"nctId":"NCT04554680","phase":"PHASE2","title":"Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2020-12-30","conditions":["Thyroid Cancer"],"enrollment":5,"completionDate":"2022-04"},{"nctId":"NCT01426386","phase":"PHASE2","title":"A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-09","conditions":["Infertility"],"enrollment":265,"completionDate":"2013-03"},{"nctId":"NCT03276988","phase":"PHASE1,PHASE2","title":"Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients","status":"COMPLETED","sponsor":"Genexine, Inc.","startDate":"2017-09-07","conditions":["Total Thyroidectomy","Near-total Thyroidectomy"],"enrollment":8,"completionDate":"2020-01-20"},{"nctId":"NCT02278198","phase":"PHASE1","title":"Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-11-30","conditions":["Differentiated Thyroid Cancer"],"enrollment":5,"completionDate":"2019-09-20"},{"nctId":"NCT01969201","phase":"PHASE4","title":"FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2014-01","conditions":["Infertility"],"enrollment":710,"completionDate":"2017-08"},{"nctId":"NCT01843062","phase":"PHASE3","title":"Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-08-27","conditions":["Differentiated Thyroid Cancer"],"enrollment":233,"completionDate":"2019-03-06"},{"nctId":"NCT03857230","phase":"PHASE1","title":"The Safety and Pharmacokinetics of Primapur and Gonal-f","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2015-10-29","conditions":["Area Under Curve","Pharmacokinetics","Absorption"],"enrollment":28,"completionDate":"2016-05-10"},{"nctId":"NCT02968914","phase":"PHASE1","title":"Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-04","conditions":["Asthma","Chronic Obstructive Pulmonary Disease"],"enrollment":180,"completionDate":"2017-07-13"},{"nctId":"NCT00085293","phase":"PHASE2","title":"Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-05","conditions":["Recurrent Thyroid Cancer","Stage IVA Follicular Thyroid Cancer","Stage IVA Papillary Thyroid Cancer","Stage IVB Follicular Thyroid Cancer","Stage IVB Papillary Thyroid Cancer","Stage IVC Follicular Thyroid Cancer","Stage IVC Papillary Thyroid Cancer"],"enrollment":12,"completionDate":"2014-05"},{"nctId":"NCT00181168","phase":"PHASE2","title":"Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2001-03","conditions":["Thyroid Cancer"],"enrollment":63,"completionDate":"2003-09"},{"nctId":"NCT00926978","phase":"NA","title":"Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)","status":"TERMINATED","sponsor":"Medstar Health Research Institute","startDate":"2008-12","conditions":["Thyroid Cancer"],"enrollment":21,"completionDate":"2018-10"},{"nctId":"NCT02006680","phase":"","title":"Markers of Pubertal Suppression During Therapy for Precocious Puberty","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2013-12","conditions":["Central Precocious Puberty"],"enrollment":4,"completionDate":"2015-12"},{"nctId":"NCT02625519","phase":"PHASE4","title":"Efficacy of Urinary Vs Recombinant FSH in Oocyte Donors Based on Receptor N680S FSH Gene Polymorphism (Genodon Trial)","status":"UNKNOWN","sponsor":"Instituto Bernabeu","startDate":"2015-12","conditions":["Reproductive Techniques, Assisted"],"enrollment":180,"completionDate":"2019-03"},{"nctId":"NCT03624751","phase":"","title":"Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2018-06-30","conditions":["Thyroid Cancer"],"enrollment":300,"completionDate":"2030-06-30"},{"nctId":"NCT02454608","phase":"NA","title":"Trial of Verapamil in Chronic Rhinosinusitis","status":"TERMINATED","sponsor":"Benjamin Bleier","startDate":"2015-05","conditions":["Sinusitis","Nasal Polyps"],"enrollment":29,"completionDate":"2017-05"},{"nctId":"NCT01182285","phase":"PHASE2","title":"A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-24","conditions":["Thyroid Neoplasm"],"enrollment":13,"completionDate":"2016-04-28"},{"nctId":"NCT01183143","phase":"PHASE3","title":"Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-05-11","conditions":["Infertility","Ovulation Induction","In-Vitro Fertilization"],"enrollment":215,"completionDate":"2006-03-02"},{"nctId":"NCT00249834","phase":"PHASE4","title":"Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-09-22","conditions":["Infertility"],"enrollment":166,"completionDate":"2006-01-16"},{"nctId":"NCT01110707","phase":"PHASE2","title":"A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-01-10","conditions":["Infertility","Ovulation Induction"],"enrollment":131,"completionDate":"2006-11-15"},{"nctId":"NCT02069808","phase":"PHASE4","title":"Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation","status":"COMPLETED","sponsor":"Michigan Reproductive Medicine","startDate":"2014-04","conditions":["Egg Donation"],"enrollment":38,"completionDate":"2017-03-08"},{"nctId":"NCT01687712","phase":"PHASE3","title":"Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF","status":"COMPLETED","sponsor":"Fertility Biotech AG","startDate":"2013-11-25","conditions":["Infertility"],"enrollment":1100,"completionDate":"2016-11-14"},{"nctId":"NCT03118830","phase":"PHASE4","title":"Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-04-21","conditions":["Invitro Fertilization"],"enrollment":204,"completionDate":"2017-11-03"},{"nctId":"NCT00071838","phase":"PHASE2","title":"Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10-30","conditions":["Multiple Sclerosis, Relapsing-Remitting"],"enrollment":16,"completionDate":"2011-08-16"},{"nctId":"NCT00970359","phase":"NA","title":"Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-09","conditions":["Thyroid Cancer"],"enrollment":24,"completionDate":"2013-04"},{"nctId":"NCT01871532","phase":"PHASE4","title":"Low-dose Gonal-f® in Ovulation Induction","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-07","conditions":["Infertility","Monofollicular Development"],"enrollment":24,"completionDate":"2014-11"},{"nctId":"NCT02349945","phase":"PHASE2,PHASE3","title":"FSH Receptor Polymorphism p.N680S and Efficacy of FSH Therapy","status":"COMPLETED","sponsor":"Azienda USL Modena","startDate":"2011-01","conditions":["Male Infertility"],"enrollment":88,"completionDate":"2015-12"},{"nctId":"NCT01412918","phase":"NA","title":"Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2011-09","conditions":["Tinnitus"],"enrollment":21,"completionDate":"2014-01"},{"nctId":"NCT01653743","phase":"PHASE3","title":"Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-09","conditions":["Anovulation","Oligo-ovulation","Hypothalamic-pituitary Dysfunction","Polycystic Ovarian Syndrome"],"enrollment":81,"completionDate":"2014-12"},{"nctId":"NCT02140515","phase":"PHASE4","title":"Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism","status":"UNKNOWN","sponsor":"Royan Institute","startDate":"2012-11","conditions":["Infertility"],"enrollment":90,"completionDate":"2016-11"},{"nctId":"NCT00117650","phase":"PHASE2","title":"Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-02","conditions":["Intermittent Claudication","Peripheral Vascular Disease","Atherosclerosis"],"enrollment":289,"completionDate":"2010-03"},{"nctId":"NCT01736163","phase":"","title":"A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2012-05","conditions":["Thyroid Cancer"],"enrollment":144,"completionDate":"2012-08"},{"nctId":"NCT00137891","phase":"PHASE1","title":"Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-06","conditions":["Healthy"],"enrollment":46,"completionDate":"2005-08"},{"nctId":"NCT00196729","phase":"PHASE3","title":"Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-12","conditions":["Thyroid Neoplasms"],"enrollment":63,"completionDate":"2003-09"},{"nctId":"NCT00295763","phase":"PHASE3","title":"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-05","conditions":["Differentiated Thyroid Cancer"],"enrollment":61,"completionDate":"2006-09"},{"nctId":"NCT00525135","phase":"PHASE2","title":"Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2007-08","conditions":["Head and Neck Cancer"],"enrollment":5,"completionDate":"2009-03"},{"nctId":"NCT02244866","phase":"NA","title":"Efficacy of Pergoveris in Aged IVF Patients","status":"COMPLETED","sponsor":"Vietnam National University","startDate":"2012-10","conditions":["Infertility"],"enrollment":240,"completionDate":"2014-06"},{"nctId":"NCT01945125","phase":"NA","title":"Effects of THW and rhTSH in Glomerular Filtration Rate During RIT","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2011-10","conditions":["Other Impaired Renal Function Disorder"],"enrollment":28,"completionDate":"2014-04"},{"nctId":"NCT01100333","phase":"","title":"GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-04","conditions":["Infertility"],"enrollment":2552,"completionDate":"2011-07"},{"nctId":"NCT01115725","phase":"","title":"A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-11","conditions":["Infertility"],"enrollment":76,"completionDate":"2008-07"},{"nctId":"NCT01111084","phase":"","title":"A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-03","conditions":["Ovulation Induction"],"enrollment":410,"completionDate":"2005-06"},{"nctId":"NCT01080729","phase":"","title":"An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":["Multifollicular Stimulation"],"enrollment":25,"completionDate":"2010-02"},{"nctId":"NCT01600989","phase":"","title":"Mitochondrial Function of Immune Cells in Sepsis","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2012-05","conditions":["Shock, Septic"],"enrollment":60,"completionDate":"2013-11"},{"nctId":"NCT00298025","phase":"PHASE4","title":"A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2003-09","conditions":["Infertile Women Undergoing Assisted Reproductive Technology (ART)"],"enrollment":185,"completionDate":"2004-05"},{"nctId":"NCT01100346","phase":"","title":"Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-01","conditions":["Infertility"],"enrollment":30,"completionDate":"2010-09"},{"nctId":"NCT01225835","phase":"PHASE4","title":"Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-10","conditions":["Infertility"],"enrollment":124,"completionDate":"2013-06"},{"nctId":"NCT01081626","phase":"PHASE4","title":"Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-03","conditions":["Ovulation Induction"],"enrollment":310,"completionDate":"2011-03"},{"nctId":"NCT00829244","phase":"PHASE4","title":"CONSORT Randomized Controlled Trial in Assisted Reproductive Technology","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-08","conditions":["Infertility"],"enrollment":200,"completionDate":"2010-01"},{"nctId":"NCT01075815","phase":"PHASE2","title":"A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-11","conditions":["Infertility","Ovulation Induction"],"enrollment":76,"completionDate":"2010-10"},{"nctId":"NCT01185704","phase":"PHASE3","title":"Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-11","conditions":["Polycystic Ovarian Syndrome"],"enrollment":136,"completionDate":"2012-02"},{"nctId":"NCT01210144","phase":"PHASE4","title":"EXpression PRofile Endometrium Samples Study","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-08","conditions":["In Vitro Fertilization"],"enrollment":27,"completionDate":"2010-08"},{"nctId":"NCT01084265","phase":"PHASE3","title":"A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-02","conditions":["Hypogonadism"],"enrollment":31,"completionDate":"2005-12"},{"nctId":"NCT00275171","phase":"PHASE2","title":"rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter","status":"COMPLETED","sponsor":"Steen Bonnema","startDate":"2006-02","conditions":["Nodular Goiter"],"enrollment":90,"completionDate":"2009-09"},{"nctId":"NCT00328926","phase":"PHASE4","title":"Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2006-03","conditions":["Hypogonadotropic Hypogonadism"],"enrollment":11,"completionDate":"2012-05"},{"nctId":"NCT00604318","phase":"PHASE4","title":"Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer","status":"COMPLETED","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2008-02","conditions":["Thyroid Cancer"],"enrollment":56,"completionDate":"2012-02"},{"nctId":"NCT01760278","phase":"PHASE4","title":"Assessment of Implantation Potential of Embryos by Time-lapse Technology","status":"UNKNOWN","sponsor":"Bloom IVF and Fertility Centre","startDate":"2012-12","conditions":["Embryo/Fetus Death","Blastocyst Disintegration","Aneuploidy","Complication of Implant","Chemical Pregnancy"],"enrollment":200,"completionDate":"2013-04"},{"nctId":"NCT01662180","phase":"","title":"Predicting Ovarian Response in Artificial Insemination With Low Stimulation","status":"UNKNOWN","sponsor":"Isala","startDate":"2012-12","conditions":["Subfertility"],"enrollment":510,"completionDate":"2015-03"},{"nctId":"NCT00884221","phase":"PHASE3","title":"MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-07","conditions":["Infertility"],"enrollment":749,"completionDate":"2011-01"},{"nctId":"NCT00493376","phase":"","title":"Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer","status":"TERMINATED","sponsor":"British Columbia Cancer Agency","startDate":"2007-08","conditions":["Cervix Cancer"],"enrollment":1,"completionDate":""},{"nctId":"NCT00001934","phase":"PHASE2","title":"Zenapax to Treat Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1999-09","conditions":["Multiple Sclerosis"],"enrollment":22,"completionDate":"2008-09"},{"nctId":"NCT00145366","phase":"PHASE2","title":"rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2002-04","conditions":["Benign Nontoxic and Toxic Goiter","Graves' Disease"],"enrollment":110,"completionDate":"2005-07"}],"_emaApprovals":[{"date":"2000-03-09","status":"Authorised","company":"SANOFI B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Thyrogen"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000180238","MMSL":"14103","NDDF":"002112","UNII":"AVX3D5A4LM","VUID":"4021142","VANDF":"4021142","INN_ID":"7668","RXNORM":"10579","UMLSCUI":"C2587204","chemblId":"CHEMBL1201533","ChEMBL_ID":"CHEMBL1201533","KEGG_DRUG":"D06120","DRUGBANK_ID":"DB00024","PUBCHEM_CID":"32281","SNOMEDCT_US":"326013007","SECONDARY_CAS_RN":"9002-71-5","MESH_DESCRIPTOR_UI":"D057073"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1953-","companyName":"Sanofi","relationship":"Original Developer"},{"period":"2000","companyName":"Sanofi B.V.","relationship":"EMA Licensee"}],"publicationCount":28,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"H01AB01","allCodes":["H01AB01","V04CJ01"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Sanofi","companyId":"sanofi","modality":"Recombinant protein","firstApprovalDate":"1953","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1953-05-26T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1953-05-26T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1953-05-26T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1953-05-26T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1953-05-26T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1953-05-26T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-08-12T00:00:00.000Z","mah":"GENZYME","brand_name_local":null,"application_number":"BLA020898"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:49:20.578763+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}